22664-55-7

Basic information

• Product Name: metipranolol
• Synonyms: 4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethylphenol 1-acetate;Disorat;Methypranol;Trimepranol;VUFB-6453;Glauline;Glausyn;4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)-2,3,6-TRIMETHYLPHENYL ACETATE
• CAS NO: 22664-55-7
• Molecular Formula: C₁₇H₂₇NO₄
• Molecular Weight: 309.4006
• EINECS: 245-151-5
• Mol File: 22664-55-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 105-107℃
• Boiling Point: 458.7°Cat760mmHg
• Flash Point: 231.2°C
• Appearance: /
• Density: 1.068
• Vapor Pressure: 3.29E-09mmHg at 25°C
• Refractive Index: 1.512
• CAS DataBase Reference: metipranolol(CAS DataBase Reference)
• NIST Chemistry Reference: metipranolol(22664-55-7)
• EPA Substance Registry System: metipranolol(22664-55-7)

Safety Data

• Hazardous Substances Data: 22664-55-7(Hazardous Substances Data)

Usage

Description

Metipranolol, also known as 3-(Propan-2-ylamino)propane-1,2-diol, is a non-cardioselective beta-blocker with a 4-acetoxy-2,3,5-trimethylphenoxy group substitution on the primary hydroxy group. It is primarily used in the management of open-angle glaucoma by lowering intraocular pressure.

Uses

Used in Ophthalmology:
Metipranolol is used as a medication for the treatment of open-angle glaucoma. It functions by reducing intraocular pressure, which helps in managing the progression of the disease and preventing further damage to the optic nerve.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, metipranolol is utilized as an active pharmaceutical ingredient (API) for the development of glaucoma treatment medications. It is the key component in the formulation of drugs like OptiPranolol, which is manufactured by Bausch & Lomb Pharmaceuticals.

InChI:InChI=1/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

FLUORESCENCE BASED DETECTION OF SUBSTANCES

A method for the fluorescent detection of a substance, the method comprising providing particles comprising a metal or a metal oxide core, wherein one or more optionally fluorescently tagged antibodies or human specific peptide nucleic acid (PNA) oligomers for binding to a substance is/are bound, directly or indirectly, to the surface of the metal or metal oxide; contacting a substrate, which may or may not have the substance on its surface, with the particles for a time sufficient to allow the antibody/PNA oligomer to bind with the substance; removing those particles which have not bound to the substrate; if the antibodies or PNA oligomers are not fluorescently tagged, contacting the substrate with one or more fluorophores that selectively bind with the antibody and/or substance, then optionally washing the substrate to remove unbound fluorophores; and illuminating the substrate with appropriate radiation to show the fluorophores on the substrate.

Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate

The present invention provides a pharmaceutical composition for controlled release of 4-(2-hydroxy-3-isopropylamino-propoxy) indole in the intestinal tract, admixed with sodium lauryl sulphate, and enteric coated.